Group items tagged

Drug testing is a crucial part of many people's lives. Whether you're applying for a job in the law enforcement field, military, or pharmacy industry, it can be difficult to find out what drugs are on your application. Luckily, there are new ways to test yourself at home to see if you have any traces of drugs inside of you. WHERE TO FIND DRUG TESTS There are a variety of at-home drug tests available on the market. Drug tests can be found at most pharmacies and online retailers, like Drug Test City. Some of these sites are free, while others charge a fee. Here are some tips to help you choose the right site for your needs: Make sure the site is reputable. There are many scam sites out there that will take your money and not deliver on their promises. Do some research to make sure the site you're considering is legitimate. Consider the cost. Some sites charge a fee for their services, while others are free. Decide what you're willing to spend before you start your search. Compare features. Not all drug testing sites are created equal. Some offer more comprehensive services than others. Take a look at what each site has to offer and choose the one that best meets your needs.

The Association of the British Pharmaceutical Industry (ABPI) has supported the Department of Health and Social Care's recommendation to 'aggressively expedite and roll out new medicines' that have gone through trials. The ABPI welcomes government report on cancer services in England and the opportunity it provides to refocus how the pharmaceutical industry, NHS and government can improve the lives of cancer patients. David Watson, executive director, Patient Access at the ABPI, said: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in NHS cancer care. "We are pleased that the report reflects concerns about variable access to cancer medicines. We support the Committee's recommendations to 'aggressively expedite and roll out new medicines' that have gone through trials and to ensure regulatory innovation results in swift uptake in the UK.

The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) has published a report that demonstrated the importance of the collaboration between industry and the NHS to improve patient outcomes across the UK. Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments in these areas continues to be below the average of similar countries in Europe. The report, 'Transforming Lives, Improving Health Outcomes', has highlighted four initiatives where effective partnerships between the NHS, patient organisations and industry have helped to tackle unwarranted variation in the uptake of innovative medicines. Transforming Lives, Improving Health Outcomes also called for a systemwide secondary prevention strategy covering all parts of the health system creating a barrier to wider and consistent uptake of innovative medicine. It also noted that newly created Integrated Care Systems have the potential to improve preventative treatment. The report data also showed a 51% variation of uptake of three types of medicines related to diabetes between NHS Trusts in England.

When it comes to supplements, more and more people are starting to become interested in them. This is because supplements have a lot of benefits that can improve a person's health in many ways. However, with the increasing popularity of supplements also comes an increase in the number of low-quality and ineffective supplements on the market. Because of this, it is important for people who are interested in taking supplements to know how to choose quality ones that will be beneficial to their health. In this article, we will discuss some tips on how to do just that. CHOOSE SUPPLEMENTS FROM A REPUTABLE COMPANY Finally, one of the best ways to ensure that you're getting a quality supplement is to choose one from a reputable company. There are many different supplement companies out there, but not all of them are created equal. Some companies are more interested in making money than they are in providing their customers with safe and effective products. Therefore, when you're looking for supplements, it's important to do some research on the different companies that sell them. See if there have been any complaints filed against the company or if their products have been recalled by the FDA. Also, look for customer reviews of the company's products to see what other people have thought about them. As explained by the folks from Supplement First, A good supplement company will have no problem providing you with this information and will be happy to answer any questions you have. Doing some research on the company beforehand can save you a lot of time and money in the long run.

The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21). Various types of cholesterol are thought to have either healthy or unhealthy effects. Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but only in white participants, the study published in the Journal of the American College of Cardiology found. In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were higher. High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.

A group of pharmacists on Saturday (July 2) took part in this year's Pride in London parade, as the annual LGBTQ+ celebration returned to the capital after three years due to the Covid-19 pandemic. Those who participated in the march called on the government to ban conversion therapy for all LGBT+ people, reform the Gender Recognition Act, and provide equal protection for LGBT+ communities against hate crime. The event which drew a crowd of a million people marked the 50th anniversary since the first ever parade in London in 1972. Amandeep Doll, head of professional belonging at RPS, said: "It was a privilege to join in the recognition of the diversity of the LGBTQI+ community and our profession, especially on such a historic occasion. Our group of pharmacists and allies from all parts of the country loved the excitement and buzz of the day."

It is important to revisit our financial situation early in the tax year and the various ways in which we could save some tax, extract cash from the business and reduce tax liabilities. We list below some of the tax planning opportunities available in the current tax year (05 April 2023 for individuals and 31 March 2023 for corporates). Salaries As a director of a limited company, you are entitled to be paid a salary for your work and so are members of your family who work for the company. Paying at least a small salary can be very beneficial, particularly when the recipient does not already have the 35 qualifying years needed for entitlement to the full single-tier state pension, which is payable to those who reach state pension age on or after 06 April 2016. To preserve entitlement to state pension, and to ensure the year counts as a qualifying year, it is advisable to pay a salary at least equal to the lower earnings limit for National Insurance Contributions (NIC) which is set at £578 per month for 2022/2023 i.e., £9,100 per annum. Salaries may be beneficial where funds are needed in a recession for example, and the company does not have sufficient reserves to pay dividends. Dividends The annual tax-free dividend allowance for 2022/2023 is £2,000. Although referred to as an "allowance", it is actually a zero-rate band and therefore uses up your basic or higher rate band as appropriate. Dividends are treated as the top slice of income and for 2022/2023, dividend income is taxed at 8.75% to the extent it falls within the basic rate band, 33.75% if it falls within the higher rate band and 39.35% to the extent it falls within the additional rate band.

Working towards its five-year strategy, the Royal Pharmaceutical Society (RPS) has put some plan in place to change its existing structure at the executive level, which could potentially render some senior positions redundant. Though the process is in nascent stage, "two roles have been identified at potential risk of redundancy," RPS said in a statement on Thursday (March 3) afternoon, adding: "This is very much at proposal stage and no final decisions or outcomes have been reached."0 It didn't specify which two roles were going to be axed, saying: "We are unable to go into the specifics of the process for individuals due to its confidential nature, but we will of course go through a fair, reasonable and confidential consultation process and are supporting the individuals involved. "No one should be in any doubt that our commitment to education and the profession's development remains the highest priority for us, and equally support for our members, thought leadership and advocacy are core to what we do as a professional leadership body."

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

More than 100 NHS clinicians have urged the National Institute for Health and Care Excellence (NICE) to change its decision - declining recommendation of romosozumab, the first new osteoporosis medication for over a decade. In a joint letter published on January 2, the clinicians warned of the consequences of barring access to the drug to those who suffer the bone-weakening disease. The joint letter, led by the Royal Osteoporosis Society (ROS), raised concern over the scarcity of the drug pipeline for osteoporosis and lack of public funding for new research. It quoted recent government research that showed the National Institute for Health Research (NIHR) invested less than £1 million in osteoporosis research in 2020-21, against the £4.6 billion per year cost to the NHS of fractures. Craig Jones, chief executive of the Royal Osteoporosis Society said: "We're calling on NICE and the applicant company to get back round the table and work with us to ensure equal access to this important new treatment.

NHS England delivered 358 million general practice (GP) appointments, including Covid-19 vaccinations, in the 12 months to October 2023, an increase of 50.9 million compared to October 2019. This equals to 44 more appointments per practice per working day, with over 70 per cent of these taking place within two weeks of booking, data published by NHSE on Thursday (30 November) showed. Health Minister, Andrea Leadsom, thanked GPs and primary care teams across the country for making it possible to deliver around 32,500 more appointments every day, which clearly demonstrate that "more people are getting the care they need, when they need it." "While this is positive news, we know that there is more to do to make it easier and quicker for patients to contact their general practice and continue to focus on delivering the Primary Care Recovery Plan," she added. The Primary Care Recovery Plan published earlier this year is focused on improving access to primary care. It provided GPs in England with £240 million to support them to embrace the latest technology to tackle the 8am rush, and handle more appointments. As of August 2023, more than 1,000 general practices had signed up to digital upgrades to make booking GP appointments easier.

Senior academic pharmacist, Professor Mahendra Patel, recently received an award for his outstanding contribution and support for the Nigerian community in the UK. The Medical Association of Nigerians across GB (MANSAG) conducted its two-day annual General and Scientific Conference on October 27 and 28 in London. The theme of the conference focussed on "Transforming Health Outcomes" to celebrate the contributions Nigerian doctors make to healthcare systems in the UK and globally. Dr Patel delivered an encouraging speech on "Leading Black And Minority Ethnic Population Research by BAME Researchers".

It is equally important to choose your eye doctor. After all, you are handing the care of your eyes to a specialist whom you trust. The eye medical care specialist takes care of your eye needs and gives complete medical care.